Mantle Cell Lymphoma Clinical Trials

49 studies are recruiting for mantle cell lymphoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

   The goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of sonrotoclax plus zanubrutinib versus zanubrutinib plus placebo.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Alabama At Birmingham Hospital, Birmingham, Alabama

   Locations

   155 in total

   Run by

   BeOne Medicines

   See if you can join NCT06742996 on ClinicalTrials.gov

2. A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

   Study consists of two main parts to explore tacabrutideg recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Alabama At Birmingham Hospital, Birmingham, Alabama

   Locations

   115 in total

   Run by

   BeOne Medicines

   See if you can join NCT05006716 on ClinicalTrials.gov

3. Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

   This research study is for people who have relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) that has not responded to two or more lines of therapy. The purpose of this study is to identify the recommended dose of allogeneic NK cells in combination with IL-2, Tafasitamab and Rituximab for …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland, Ohio

   Locations

   2 in total

   Run by

   Paolo Caimi, MD

   See if you can join NCT07225439 on ClinicalTrials.gov

4. A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

   The purpose of this study is to assess the safety and efficacy of surovatamig (formerly AZD0486) administered as monotherapy or in combination with other anticancer agents in participants with hematological malignancies

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, Boston, Massachusetts

   Locations

   65 in total

   Run by

   AstraZeneca

   See if you can join NCT06564038 on ClinicalTrials.gov

5. Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

   This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (previously untreated). Rituximab is a monoclonal antibody th…

   Stage

   Phase 3

   Ages

   60 and older

   Site

   University of Arkansas for Medical Sciences, Little Rock, Arkansas

   Locations

   238 in total

   Run by

   Alliance for Clinical Trials in Oncology

   See if you can join NCT05976763 on ClinicalTrials.gov

6. AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

   This is a non-randomized clinical trial to evaluate the safety and efficacy of CD22CART administered after lymphodepleting chemotherapy in adults with relapsed / refractory B Cell Lymphomas. All evaluable participants will be followed for overall survival (OS), progression free survival (PFS), and …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Stanford University, Palo Alto, California

   Run by

   Stanford University

   See if you can join NCT06340737 on ClinicalTrials.gov

7. Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies

   The study is designed to examine the feasibility and safety of collecting autologous hematopoietic stem cells (HSCs) to be combined with CAR T-cell therapy for patients with relapsed/refractory (r/r) hematological disease. The study will evaluate feasibility of collecting the target dose of HSCs fr…

   Stage

   Phase 1

   Ages

   18 to 85

   Site

   Cedars-Sinai Medical Center, Los Angeles, California

   Run by

   Joshua Sasine, MD, PhD

   See if you can join NCT05887167 on ClinicalTrials.gov

8. A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

   The purpose of this study is to establish the safety of novel dosing and ramp-up schedules for sonrotoclax in participants with hematological malignancies.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Moffitt Cancer Center, Tampa, Florida

   Locations

   17 in total

   Run by

   BeOne Medicines

   See if you can join NCT06697184 on ClinicalTrials.gov

9. Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax

   Background: Bruton s tyrosine kinase inhibitors (BTKi) are used to treat a form of leukemia. But taking BTKi can also increase a person s risk of developing an abnormal heart rhythm. This can cause sudden death. In this natural history study, researchers want to learn how BTKi affects the heart. Ob…

   Stage

   Not phased

   Ages

   18 to 110

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Heart, Lung, and Blood Institute (NHLBI)

   See if you can join NCT05724121 on ClinicalTrials.gov

10. LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies

    This is a phase I, interventional, single arm, open label, treatment study designed to evaluate the safety and efficacy of LV20.19 CAR -T cells with pirtobrutinib bridging and maintenance in adult patients with B cell malignancies that have failed prior therapies.

    Stage

    Phase 1

    Ages

    18 to 81

    Site

    Froedtert & the Medical College of Wisconsin, Milwaukee, Wisconsin

    Run by

    Medical College of Wisconsin

    See if you can join NCT05990465 on ClinicalTrials.gov

11. Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

    This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.

    Stage

    Phase 1

    Ages

    13 to 90

    Site

    City of Hope, Duarte, California

    Locations

    11 in total

    Run by

    Vironexis Biotherapeutics Inc.

    See if you can join NCT06533579 on ClinicalTrials.gov

12. A Long-term Extension Study of PCI-32765 (Ibrutinib)

    The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been completed according to the parent protocol, are actively rece…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    St. Joseph Hospital Center for Cancer Prevention and Treatment, Orange, California

    Locations

    175 in total

    Run by

    Janssen Research & Development, LLC

    See if you can join NCT01804686 on ClinicalTrials.gov

13. The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

    This phase II trial studies whether providing cancer treatment in the home is preferred over the traditional clinic setting and if it improves treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas. Typically, drug-related cancer care is provided at a medica…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Mayo Clinic in Florida, Jacksonville, Florida

    Run by

    Mayo Clinic

    See if you can join NCT07285044 on ClinicalTrials.gov

14. IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas

    This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, antineoplastic activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS03, a CD19 targeting antibody-drug conjugate, in patients with advanced B cell non-Hodgkin lympho…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Westmead Hospital, Westmead, New South Wales

    Locations

    13 in total

    Run by

    Iksuda Therapeutics Ltd.

    See if you can join NCT05365659 on ClinicalTrials.gov

15. Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

    This phase II trial tests the safety and effectiveness of glofitamab given in combination with pirtobrutinib in treating patients with mantle cell lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Glofitamab and obinut…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of California, Davis, Davis, California

    Locations

    3 in total

    Run by

    University of California, San Francisco

    See if you can join NCT06252675 on ClinicalTrials.gov

16. Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

    This phase I/II trial tests the safety and effectiveness of glofitamab (with obinutuzumab pretreatment), venetoclax, and lenalidomide in treating patients with newly diagnosed, high risk mantle cell lymphoma. Glofitamab and obinutuzumab are monoclonal antibodies that may interfere with the ability …

    Stage

    Phase 1

    Ages

    18 to 80

    Site

    City of Hope Medical Center, Duarte, California

    Locations

    3 in total

    Run by

    City of Hope Medical Center

    See if you can join NCT05861050 on ClinicalTrials.gov

17. Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma

    This clinical trial evaluates the influenza virus vaccination in evaluating human immune response in patients with lymphoma. Evaluating immune response may increase the understanding of how the immune system changes when patients receive treatment for lymphomas by looking at the antibody levels and…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Emory University Hospital Midtown, Atlanta, Georgia

    Locations

    2 in total

    Run by

    Emory University

    See if you can join NCT03501576 on ClinicalTrials.gov

18. Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

    This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further radiation). followed by a post-transplant graft-versus-host disease (GVH…

    Stage

    Phase 2

    Ages

    Up to 60

    Site

    Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota

    Run by

    Masonic Cancer Center, University of Minnesota

    See if you can join NCT03314974 on ClinicalTrials.gov

19. Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

    This study will assess safety and feasibility of infusing genetically modified autologous T cells transduced to express a chimeric antigen receptor targeting the B cell surface antigen Cluster of Differentiation 19 (CD19).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of California, San Francisco, San Francisco, California

    Run by

    C. Babis Andreadis

    See if you can join NCT04545762 on ClinicalTrials.gov

20. Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

    This phase II trial studies how well a donor stem cell transplant, treosulfan, fludarabine, and total-body irradiation work in treating patients with blood cancers (hematological malignancies). Giving chemotherapy and total-body irradiation before a donor stem cell transplant helps stop the growth …

    Stage

    Phase 2

    Ages

    0 and older

    Site

    Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

    Run by

    Fred Hutchinson Cancer Center

    See if you can join NCT04195633 on ClinicalTrials.gov

21. Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

    To learn if the combination of pirtobrutinib (also called LOXO-305) and venetoclax can help to control mantle cell lymphoma (MCL) that is relapsed (has come back) or refractory (has not responded to therapy).

    Stage

    Phase 2

    Ages

    18 and older

    Site

    M D Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT05529069 on ClinicalTrials.gov

22. Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients

    To learn if the chemotherapy-free combination of pirtobrutinib (also called LOXO-305) and rituximab can help provide long term remission in low and intermediate risk MCL.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT06263491 on ClinicalTrials.gov

23. Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

    The purpose of this study is to determine if giving an experimental drug called venetoclax in combination with lenalidomide and rituximab is safe and effective for treating people with Mantle Cell Lymphoma (MCL).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope Medical center, Duarte, California

    Locations

    4 in total

    Run by

    City of Hope Medical Center

    See if you can join NCT03523975 on ClinicalTrials.gov

24. Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma

    This phase II trial studies the side effects of an escalated ramp-up of sonrotoclax following initial debulking with zanubrutinib or rituximab in treating patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL) that is newly diagnosed, has …

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

    Run by

    Fred Hutchinson Cancer Center

    See if you can join NCT06839053 on ClinicalTrials.gov

25. Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

    Patients will receive one of two conditioning regimens (BEAM or CBV) before receiving an autologous stem cell transplant (ASCT). If patients achieve either complete, partial, or stable response following ASCT, they will receive an IV dose of Polatuzumab Vedotin once every 21 days until they receive…

    Stage

    Phase 1

    Ages

    12 to 70

    Site

    New York Medical Center, Valhalla, New York

    Run by

    New York Medical College

    See if you can join NCT04491370 on ClinicalTrials.gov